Developer docs
API playgroundTry for free, no card

Search company profiles

NanoTag Biotechnologies

Full company profile

uuid000e7f6

Namestring
NanoTag Biotechnologies
Legal namestring
NanoTag Biotechnologies GmbH
Websiteurl
nano-tag.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

NanoTag Biotechnologies GmbH is a privately held German biotechnology company founded in 2015 and headquartered in Göttingen, Germany (Commercial Register HRB 204645; Managing Director Dr. Hansjörg Götzke). The company specializes in single-domain antibodies (sdAbs, also called nanobodies) derived from camelid heavy-chain-only antibodies, and operates a proprietary platform spanning discovery, engineering, conjugation, and recombinant production. Core technology assets include the patented ALFA-tag system (a 13-amino-acid epitope tag recognized by three complementary sdAbs across pM–nM affinity), the FluoTag-Q/X2/X4 site-specific conjugation platform with defined fluorophore stoichiometry, Selector Resins for affinity purification, Smart Secondaries replacing conventional secondary antibodies, the Celline B-lymphocyte discovery method, FX fixation cassettes, and recombinant heavy-chain antibodies (rHcAbs) fused to IgG Fc domains.

The commercial portfolio comprises off-the-shelf catalog products — including FluoTag fluorescent sdAb conjugates, Smart Secondaries, Selector Resins (GFP, RFP, TagFP, ALFA variants), unconjugated sdAbs, and rHcAbs — sold primarily through a Shopify-powered direct e-commerce webshop with EUR/USD dual-region pricing, supplemented by a Scientist.com marketplace listing. A second revenue stream consists of CRO services for custom sdAb discovery, protein production, and modification, contracted on a project basis. A third stream is technology licensing, exemplified by the EUR 1 million option exercise fee received from BioNTech in May 2024 under a 2022 Research Collaboration and License Agreement covering the ALFA system for oncology and infectious disease applications, with potential development, regulatory, commercial milestones and royalties. Products serve academic and biotech life science R&D users in super-resolution microscopy (STED, dSTORM, DNA-PAINT, MINFLUX, Expansion Microscopy), immunofluorescence, affinity purification, biosensors, cryo-EM, and crystallography.

Short descriptiontext

NanoTag Biotechnologies is a privately held Göttingen-based biotech (founded 2015) that discovers, engineers, and commercializes camelid single-domain antibodies (sdAbs/nanobodies) as off-the-shelf fluorescent reagents, affinity resins, and secondary antibodies for academic and biotech researchers, with additional custom CRO services and therapeutic licensing deals such as the 2024 BioNTech ALFA agreement.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGöttingen, Germany
HQ citystring
Göttingen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-domain antibodies, nanobody reagents, antibody discovery services, super-resolution microscopy, affinity purification resins
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAG
Nanobodies & Alternative Antibody Scaffolds
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biotechnology Reagents
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Off-the-shelf sdAb Product Sales
TypeOne Time License
Description

NanoTag sells a broad catalog of validated sdAb products through its e-commerce webshop, including FluoTags (fluorescent conjugates), Smart Secondaries, Selector Resins, unconjugated sdAbs, and related reagents. Products are available in multiple conjugation formats (fluorophores, biotin, HRP, DBCO, etc.) with per-product pricing ranging from approximately €130 to €420+ per unit.

nano-tag.com
2Custom CRO Services
TypeProfessional Services
Description

Tailored sdAb discovery services, custom protein production, advanced sdAb modifications, and functional validations for specific project needs. Services are highly customized and contracted on a project basis.

nano-tag.com
3Technology Licensing (ALFA System)
TypeLicensing Royalties
Description

Under the May 2024 BioNTech agreement, NanoTag received a EUR 1 million option exercise fee and is eligible for potential additional development, regulatory, and commercial milestone payments plus royalty payments on products advanced under the licensing agreement.

nano-tag.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details6 tiers
1FluoTag-X4 anti-GFP (200 µL) — flagship fluorescent primary reagent
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€420.00 per 200 µL unit; available with abberior STAR dyes, Janelia Fluor 635b, Atto488, Alexa Fluor 568/647, Atto643

nano-tag.com
2FluoTag-X2 anti-Mouse Ig kappa light chain (500 µL) — Smart Secondary reagent
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€205.00 per 500 µL unit; available in multiple fluorophore conjugates

nano-tag.com
3sdAb anti-Mouse Ig kappa light chain (250 µg) — unconjugated or conjugated secondary
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price range: €290.00 – €655.00 depending on conjugation format (Biotin, DBCO, HRP, unconjugated C-terminal Cys)

nano-tag.com
4GFP-ALFA Control Protein (100 µg) — control standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€130.00 per 100 µg unit

nano-tag.com
5TagFP Selector (2 mL slurry) — affinity resin
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€290.00 per 2 mL slurry

nano-tag.com
6Custom CRO Services — tailored project pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / not publicly disclosed; custom services for sdAb discovery, protein production, and sdAb modification are contracted on a project basis

nano-tag.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1FluoTags
Description

Trademark for camelid single-domain antibodies conjugated to chemical fluorophores, available as FluoTag-Q, FluoTag-X2, and FluoTag-X4 variants with defined fluorophore conjugation.

nano-tag.com
+5 more records
Core offering1 text field

NanoTag Biotechnologies manufactures and sells single-domain antibody (sdAb / nanobody) based research reagents — including fluorescent FluoTag® conjugates, Smart Secondaries® species-specific secondary nanobodies, and Selector affinity resins — produced recombinantly in microbial and mammalian expression systems. The company also licenses its proprietary ALFA-tag system and provides custom contract research services for sdAb discovery and recombinant protein production. Customers are academic, biotech, and pharmaceutical researchers using these reagents for super-resolution microscopy, immunofluorescence, and affinity purification.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ALFA Selector ST achieves Kd = 26 pM affinity for ALFA-tagged proteins, enabling high-capacity pull-down with negligible background
+3 more records
Product overview1 text field

NanoTag Biotechnologies is a biotechnology company specializing in single-domain antibodies (sdAbs), also known as nanobodies, derived from camelids. The company offers a comprehensive portfolio of reagent products and contract research services. Core reagent products include FluoTag® fluorescent sdAb conjugates (FluoTag-Q with 1 fluorophore, FluoTag-X2 with 2 fluorophores, and FluoTag-X4 with 4 fluorophores) for super-resolution microscopy, Smart Secondaries® species-specific secondary nanobodies, Selector Resins (GFP, RFP, TagFP, and ALFA Selectors) for affinity purification, the ALFA System tag technology, and recombinant heavy-chain antibodies (rHcAbs). The company also provides CRO services for custom sdAb discovery and protein production. Key technology platforms include FX Technology for improved post-fixation, Celline for B lymphocyte-based sdAb discovery, OneStep Immunofluorescence, and Multiplexing technology for species-independent multi-target staining.

Product and service11 records
1FluoTag®-Q single-domain antibody conjugates
CategoryFluorescent Antibody Reagents
Description

Fluorescently labeled sdAbs carrying exactly one fluorophore per protein molecule, positioned within 1.5 nm of the antigen-binding surface. Designed for epitope counting and highly linear quantitative fluorescence analyses in research imaging.

2FluoTag®-X2 single-domain antibody conjugates
CategoryFluorescent Antibody Reagents
Description

sdAbs carrying two fluorophores per protein molecule, providing up to 2-fold brighter signal than FluoTag-Q while maintaining small size for optimal tissue penetration in immunofluorescence and super-resolution microscopy.

3FluoTag®-X4 single-domain antibody conjugates
CategoryFluorescent Antibody Reagents
Description

Blend of two different sdAbs each carrying two fluorophores, delivering up to 4 fluorophores per target for high-signal super-resolution microscopy, including specific catalog items anti-GFP and anti-Halo.

4Smart Secondaries® secondary nanobodies
CategorySecondary Antibody Reagents
Description

Single-domain antibodies recognizing conventional immunoglobulins with species and isotype specificity, replacing conventional polyclonal secondary antibodies. Monovalent binding prevents cluster formation, enabling OneStep Immunofluorescence and species-independent multiplexing.

5Selector Resins affinity purification resins
CategoryAffinity Purification Resins
Description

Affinity resins based on controlled covalent oriented immobilization of sdAbs on 4% cross-linked agarose or magnetic agarose beads, including GFP Selector, RFP Selector, TagFP Selector, and ALFA Selector (ST, PE, CE) variants. Eliminate Ig heavy/light chain contamination in pull-down eluates even under denaturing conditions.

6ALFA System target labeling technology (licensed to BioNTech)
CategoryEpitope Tag Technology Platform
Description

Patented 13-amino-acid epitope tag (SRLEEELRRRLTE) recognized by three complementary sdAbs spanning pM to nM affinity. Licensed exclusively to BioNTech for therapeutic applications; available to researchers as imaging, immobilization, and affinity purification reagents.

7Recombinant Heavy-chain Antibodies (rHcAbs)
CategoryRecombinant Antibody Reagents
Description

Single-domain antibodies genetically fused to immunoglobulin Fc domains (Mouse or Rabbit IgG Fc), creating divalent recombinant antibodies that combine nanobody-level specificity with conventional Fc-based detection flexibility and signal amplification.

8Bi-specific sdAb Fusions (Diabodies)
CategoryCustom sdAb Engineering Services
Description

Custom-designed fusions of two sdAbs targeting the same or different molecules, used as adaptor entities bringing two target molecules in tight contact or to increase apparent binding affinity via two-site binding. Delivered with cloning and expression services in prokaryotic and eukaryotic systems using ready-to-use vector systems.

9FX Technology sdAbs (Fixation Cassettes)
CategoryMicroscopy Reagents
Description

sdAbs equipped with short amino acid cassettes carrying multiple primary amines that improve post-fixation properties for STORM, DNA-PAINT, and expansion microscopy applications, providing ProteinaseK-resistant anchor points.

10sdAb Discovery Services (CRO)
CategoryContract Research Services
Description

Custom-tailored contract research service for discovery of single-domain antibodies against specific protein targets, including screening, selection, engineering, and functional validation using the proprietary Celline B-lymphocyte selection platform.

11Protein Production Services (CRO)
CategoryContract Research Services
Description

Recombinant protein production service using bacterial, yeast, and mammalian cell culture systems, including GMP-compatible scalable production for advanced sdAb modifications and functional validations.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1BioNTech SE
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-05-22
Description

BioNTech has exercised an exclusive option under a 2022 Research Collaboration and License Agreement to evaluate NanoTag's ALFA tagging system in oncology and infectious diseases, in both preclinical and clinical settings. NanoTag received a EUR 1 million option exercise fee. The agreement provides for potential additional development, regulatory, and commercial milestone payments, plus royalty payments on products advanced by BioNTech. The ALFA system enables specific labeling of target proteins using a rationally designed peptide tag bound by NanoTag's sdAbs.

nano-tag.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1ChromoTek (Proteintech Group)
TypeDirect peer
Description

Most direct competitor in the sdAb/nanobody reagent space, offering GFP-Trap, RFP-Trap, and similar camelid-derived affinity reagents. Now backed by Proteintech Group, providing much larger distribution and catalog than NanoTag. Highly comparable product category, customer base, and application focus.

TypeDirect peer
Description

German-based antibody reagent company specializing in neuroscience research products, including recombinant antibodies and secondary reagents. Comparable in scale and customer base (academic/biomedical research), with overlapping product categories in secondary detection.

TypeBroad incumbent
Description

Established specialty manufacturer of secondary antibodies and immunoreagents for research. Competes with NanoTag's Smart Secondaries line via conventional polyclonal secondary antibodies, though lacks sdAb/single-domain scaffold advantages.

TypeBroad incumbent
Description

Global leader in research antibodies and life science reagents, recently acquired by Danaher. Offers an extensive antibody catalog with growing recombinant and nanobody offerings, competing with NanoTag across most research reagent categories with far broader portfolio and distribution.

TypeBroad incumbent
Description

Major US-based antibody reagent company focused on signaling pathway and neuroscience research. Competes with NanoTag's neuroscience rHcAb product line and broader secondary detection reagents, with significantly larger catalog and commercial footprint.

TypeBroad incumbent
Description

Global life science giant with broad antibody, reagent, and instrument portfolio including Invitrogen and Thermo Scientific brands. Competes with NanoTag through its primary/secondary antibody catalog, affinity purification products, and custom CRO services, with vastly greater resources.

TypeBroad incumbent
Description

Diversified life science research and clinical diagnostics company with antibody products, protein purification resins, and imaging reagents. Overlaps with NanoTag's Selector Resin product line (affinity purification) and research antibody catalog.

TypeBroad incumbent
Description

Major antibody manufacturer with extensive catalog of polyclonal, monoclonal, and recombinant antibodies. Parent of ChromoTek (NanoTag's closest direct competitor), making it a particularly relevant broader incumbent competing across multiple NanoTag product categories.

TypeEmerging player
Description

Clinical-stage immunology company developing nanobody-based therapeutics (efgartigimod/VYVGART franchise approved for myasthenia gravis and ITP). Comparable in nanobody/sdAb technology foundation but focused on therapeutic applications rather than research reagents — emerging competitive overlap if NanoTag advances ALFA into therapeutics.

TypeOthers
Description

French CRO offering custom antibody and sdAb discovery services using yeast two-hybrid and phage display platforms. Comparable CRO business model to NanoTag's custom sdAb discovery services, though with different underlying discovery technologies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NanoTag Biotechnologies

Biotechnology Reagentsnano-tag.com

NanoTag Biotechnologies is a privately held Göttingen-based biotech (founded 2015) that discovers, engineers, and commercializes camelid single-domain antibodies (sdAbs/nanobodies) as off-the-shelf fluorescent reagents, affinity resins, and secondary antibodies for academic and biotech researchers, with additional custom CRO services and therapeutic licensing deals such as the 2024 BioNTech ALFA agreement.

What NanoTag Biotechnologies does

NanoTag Biotechnologies GmbH is a privately held German biotechnology company founded in 2015 and headquartered in Göttingen, Germany (Commercial Register HRB 204645; Managing Director Dr. Hansjörg Götzke). The company specializes in single-domain antibodies (sdAbs, also called nanobodies) derived from camelid heavy-chain-only antibodies, and operates a proprietary platform spanning discovery, engineering, conjugation, and recombinant production. Core technology assets include the patented ALFA-tag system (a 13-amino-acid epitope tag recognized by three complementary sdAbs across pM–nM affinity), the FluoTag-Q/X2/X4 site-specific conjugation platform with defined fluorophore stoichiometry, Selector Resins for affinity purification, Smart Secondaries replacing conventional secondary antibodies, the Celline B-lymphocyte discovery method, FX fixation cassettes, and recombinant heavy-chain antibodies (rHcAbs) fused to IgG Fc domains.

The commercial portfolio comprises off-the-shelf catalog products — including FluoTag fluorescent sdAb conjugates, Smart Secondaries, Selector Resins (GFP, RFP, TagFP, ALFA variants), unconjugated sdAbs, and rHcAbs — sold primarily through a Shopify-powered direct e-commerce webshop with EUR/USD dual-region pricing, supplemented by a Scientist.com marketplace listing. A second revenue stream consists of CRO services for custom sdAb discovery, protein production, and modification, contracted on a project basis. A third stream is technology licensing, exemplified by the EUR 1 million option exercise fee received from BioNTech in May 2024 under a 2022 Research Collaboration and License Agreement covering the ALFA system for oncology and infectious disease applications, with potential development, regulatory, commercial milestones and royalties. Products serve academic and biotech life science R&D users in super-resolution microscopy (STED, dSTORM, DNA-PAINT, MINFLUX, Expansion Microscopy), immunofluorescence, affinity purification, biosensors, cryo-EM, and crystallography.

NanoTag Biotechnologies firmographics

Firmographics
Name
NanoTag Biotechnologies
Legal name
NanoTag Biotechnologies GmbH
Website
https://nano-tag.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NanoTag Biotechnologies is a privately held Göttingen-based biotech (founded 2015) that discovers, engineers, and commercializes camelid single-domain antibodies (sdAbs/nanobodies) as off-the-shelf fluorescent reagents, affinity resins, and secondary antibodies for academic and biotech researchers, with additional custom CRO services and therapeutic licensing deals such as the 2024 BioNTech ALFA agreement.
Ownership category
akta.pro rank

NanoTag Biotechnologies industry classification

Industry
Product category
Biotechnology Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAG
Nanobodies & Alternative Antibody Scaffolds
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Single-domain antibodies
  • Nanobody reagents
  • Antibody discovery services
  • Super-resolution microscopy
  • Affinity purification resins

Where NanoTag Biotechnologies is headquartered

Location

Headquarters

HQ city
Göttingen
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

NanoTag Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Off-the-shelf sdAb Product Sales: NanoTag sells a broad catalog of validated sdAb products through its e-commerce webshop, including FluoTags (fluorescent conjugates), Smart Secondaries, Selector Resins, unconjugated sdAbs, and related reagents. Products are available in multiple conjugation formats (fluorophores, biotin, HRP, DBCO, etc.) with per-product pricing ranging from approximately €130 to €420+ per unit.
  2. Custom CRO Services: Tailored sdAb discovery services, custom protein production, advanced sdAb modifications, and functional validations for specific project needs. Services are highly customized and contracted on a project basis.
  3. Technology Licensing (ALFA System): Under the May 2024 BioNTech agreement, NanoTag received a EUR 1 million option exercise fee and is eligible for potential additional development, regulatory, and commercial milestone payments plus royalty payments on products advanced under the licensing agreement.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFluoTag-X4 anti-GFP (200 µL) — flagship fluorescent primary reagent
Unit PricingPay-as-you-goFluoTag-X2 anti-Mouse Ig kappa light chain (500 µL) — Smart Secondary reagent
Unit PricingPay-as-you-gosdAb anti-Mouse Ig kappa light chain (250 µg) — unconjugated or conjugated secondary
Unit PricingPay-as-you-goGFP-ALFA Control Protein (100 µg) — control standard
Unit PricingPay-as-you-goTagFP Selector (2 mL slurry) — affinity resin
OtherPay-as-you-goCustom CRO Services — tailored project pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

NanoTag Biotechnologies product offering

Product offering

Core offering

NanoTag Biotechnologies manufactures and sells single-domain antibody (sdAb / nanobody) based research reagents — including fluorescent FluoTag® conjugates, Smart Secondaries® species-specific secondary nanobodies, and Selector affinity resins — produced recombinantly in microbial and mammalian expression systems. The company also licenses its proprietary ALFA-tag system and provides custom contract research services for sdAb discovery and recombinant protein production. Customers are academic, biotech, and pharmaceutical researchers using these reagents for super-resolution microscopy, immunofluorescence, and affinity purification.

Product overview

NanoTag Biotechnologies is a biotechnology company specializing in single-domain antibodies (sdAbs), also known as nanobodies, derived from camelids. The company offers a comprehensive portfolio of reagent products and contract research services. Core reagent products include FluoTag® fluorescent sdAb conjugates (FluoTag-Q with 1 fluorophore, FluoTag-X2 with 2 fluorophores, and FluoTag-X4 with 4 fluorophores) for super-resolution microscopy, Smart Secondaries® species-specific secondary nanobodies, Selector Resins (GFP, RFP, TagFP, and ALFA Selectors) for affinity purification, the ALFA System tag technology, and recombinant heavy-chain antibodies (rHcAbs). The company also provides CRO services for custom sdAb discovery and protein production. Key technology platforms include FX Technology for improved post-fixation, Celline for B lymphocyte-based sdAb discovery, OneStep Immunofluorescence, and Multiplexing technology for species-independent multi-target staining.

Differentiator

Problem solved

Functional benefit

Brands

  • FluoTags: Trademark for camelid single-domain antibodies conjugated to chemical fluorophores, available as FluoTag-Q, FluoTag-X2, and FluoTag-X4 variants with defined fluorophore conjugation.
  • Smart Secondaries
  • Selector Resins
  • ALFA System
  • Celline
  • FX Technology

Products and services

  • FluoTag®-Q single-domain antibody conjugates Fluorescently labeled sdAbs carrying exactly one fluorophore per protein molecule, positioned within 1.5 nm of the antigen-binding surface. Designed for epitope counting and highly linear quantitative fluorescence analyses in research imaging.
  • FluoTag®-X2 single-domain antibody conjugates sdAbs carrying two fluorophores per protein molecule, providing up to 2-fold brighter signal than FluoTag-Q while maintaining small size for optimal tissue penetration in immunofluorescence and super-resolution microscopy.
  • FluoTag®-X4 single-domain antibody conjugates Blend of two different sdAbs each carrying two fluorophores, delivering up to 4 fluorophores per target for high-signal super-resolution microscopy, including specific catalog items anti-GFP and anti-Halo.
  • Smart Secondaries® secondary nanobodies Single-domain antibodies recognizing conventional immunoglobulins with species and isotype specificity, replacing conventional polyclonal secondary antibodies. Monovalent binding prevents cluster formation, enabling OneStep Immunofluorescence and species-independent multiplexing.
  • Selector Resins affinity purification resins Affinity resins based on controlled covalent oriented immobilization of sdAbs on 4% cross-linked agarose or magnetic agarose beads, including GFP Selector, RFP Selector, TagFP Selector, and ALFA Selector (ST, PE, CE) variants. Eliminate Ig heavy/light chain contamination in pull-down eluates even under denaturing conditions.
  • ALFA System target labeling technology (licensed to BioNTech) Patented 13-amino-acid epitope tag (SRLEEELRRRLTE) recognized by three complementary sdAbs spanning pM to nM affinity. Licensed exclusively to BioNTech for therapeutic applications; available to researchers as imaging, immobilization, and affinity purification reagents.
  • Recombinant Heavy-chain Antibodies (rHcAbs) Single-domain antibodies genetically fused to immunoglobulin Fc domains (Mouse or Rabbit IgG Fc), creating divalent recombinant antibodies that combine nanobody-level specificity with conventional Fc-based detection flexibility and signal amplification.
  • Bi-specific sdAb Fusions (Diabodies) Custom-designed fusions of two sdAbs targeting the same or different molecules, used as adaptor entities bringing two target molecules in tight contact or to increase apparent binding affinity via two-site binding. Delivered with cloning and expression services in prokaryotic and eukaryotic systems using ready-to-use vector systems.
  • FX Technology sdAbs (Fixation Cassettes) sdAbs equipped with short amino acid cassettes carrying multiple primary amines that improve post-fixation properties for STORM, DNA-PAINT, and expansion microscopy applications, providing ProteinaseK-resistant anchor points.
  • sdAb Discovery Services (CRO) Custom-tailored contract research service for discovery of single-domain antibodies against specific protein targets, including screening, selection, engineering, and functional validation using the proprietary Celline B-lymphocyte selection platform.
  • Protein Production Services (CRO) Recombinant protein production service using bacterial, yeast, and mammalian cell culture systems, including GMP-compatible scalable production for advanced sdAb modifications and functional validations.

Quantifiable outcome

  • ALFA Selector ST achieves Kd = 26 pM affinity for ALFA-tagged proteins, enabling high-capacity pull-down with negligible background
  • +3 more outcomes

Companies that use NanoTag Biotechnologies

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

NanoTag Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

NanoTag Biotechnologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioNTech SEflagshipOEM/ Whitelabel/ Licensing Partner · 22 May 2024BioNTech has exercised an exclusive option under a 2022 Research Collaboration and License Agreement to evaluate NanoTag's ALFA tagging system in oncology and infectious diseases, in both preclinical and clinical settings. NanoTag received a EUR 1 million option exercise fee. The agreement provides for potential additional development, regulatory, and commercial milestone payments, plus royalty payments on products advanced by BioNTech. The ALFA system enables specific labeling of target proteins using a rationally designed peptide tag bound by NanoTag's sdAbs.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

NanoTag Biotechnologies competitors and assessment

Company assessment

Direct peers

  • ChromoTek (Proteintech Group): Most direct competitor in the sdAb/nanobody reagent space, offering GFP-Trap, RFP-Trap, and similar camelid-derived affinity reagents. Now backed by Proteintech Group, providing much larger distribution and catalog than NanoTag. Highly comparable product category, customer base, and application focus.
  • Synaptic Systems: German-based antibody reagent company specializing in neuroscience research products, including recombinant antibodies and secondary reagents. Comparable in scale and customer base (academic/biomedical research), with overlapping product categories in secondary detection.

Broad incumbents

  • Jackson ImmunoResearch: Established specialty manufacturer of secondary antibodies and immunoreagents for research. Competes with NanoTag's Smart Secondaries line via conventional polyclonal secondary antibodies, though lacks sdAb/single-domain scaffold advantages.
  • Abcam: Global leader in research antibodies and life science reagents, recently acquired by Danaher. Offers an extensive antibody catalog with growing recombinant and nanobody offerings, competing with NanoTag across most research reagent categories with far broader portfolio and distribution.
  • Cell Signaling Technology: Major US-based antibody reagent company focused on signaling pathway and neuroscience research. Competes with NanoTag's neuroscience rHcAb product line and broader secondary detection reagents, with significantly larger catalog and commercial footprint.
  • Thermo Fisher Scientific (Life Science Reagents): Global life science giant with broad antibody, reagent, and instrument portfolio including Invitrogen and Thermo Scientific brands. Competes with NanoTag through its primary/secondary antibody catalog, affinity purification products, and custom CRO services, with vastly greater resources.
  • Bio-Rad Laboratories: Diversified life science research and clinical diagnostics company with antibody products, protein purification resins, and imaging reagents. Overlaps with NanoTag's Selector Resin product line (affinity purification) and research antibody catalog.
  • Proteintech Group: Major antibody manufacturer with extensive catalog of polyclonal, monoclonal, and recombinant antibodies. Parent of ChromoTek (NanoTag's closest direct competitor), making it a particularly relevant broader incumbent competing across multiple NanoTag product categories.

Emerging players

  • Argenx: Clinical-stage immunology company developing nanobody-based therapeutics (efgartigimod/VYVGART franchise approved for myasthenia gravis and ITP). Comparable in nanobody/sdAb technology foundation but focused on therapeutic applications rather than research reagents — emerging competitive overlap if NanoTag advances ALFA into therapeutics.

Others

  • Hybrigenics Services: French CRO offering custom antibody and sdAb discovery services using yeast two-hybrid and phage display platforms. Comparable CRO business model to NanoTag's custom sdAb discovery services, though with different underlying discovery technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NanoTag Biotechnologies social profiles

Digital presence

NanoTag Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NanoTag Biotechnologies leadership team

Management profile

Number of profiles

Profiles1 record

NanoTag Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NanoTag Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoTag Biotechnologies

What does NanoTag Biotechnologies do?

NanoTag Biotechnologies manufactures and sells single-domain antibody (sdAb / nanobody) based research reagents — including fluorescent FluoTag® conjugates, Smart Secondaries® species-specific secondary nanobodies, and Selector affinity resins — produced recombinantly in microbial and mammalian expression systems. The company also licenses its proprietary ALFA-tag system and provides custom contract research services for sdAb discovery and recombinant protein production. Customers are academic, biotech, and pharmaceutical researchers using these reagents for super-resolution microscopy, immunofluorescence, and affinity purification.

Is NanoTag Biotechnologies a public or private company?

NanoTag Biotechnologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NanoTag Biotechnologies founded?

NanoTag Biotechnologies was founded in 2015. It employs 11 to 50 people.

Where is NanoTag Biotechnologies based?

NanoTag Biotechnologies is headquartered in Göttingen, Germany, in the Europe region.

How does NanoTag Biotechnologies make money?

Three revenue lines are on record. Off-the-shelf sdAb Product Sales are the primary driver. The others are custom CRO Services and technology Licensing (ALFA System).

Who are NanoTag Biotechnologies's main competitors?

Direct peers on record are ChromoTek (Proteintech Group) and Synaptic Systems. Broad incumbents are Jackson ImmunoResearch, Abcam, Cell Signaling Technology, Thermo Fisher Scientific (Life Science Reagents), Bio-Rad Laboratories and Proteintech Group. Argenx is listed as an emerging player. Hybrigenics Services is listed as an others.

Does NanoTag Biotechnologies have an API?

No public API is recorded for NanoTag Biotechnologies.

What industry is NanoTag Biotechnologies in?

NanoTag Biotechnologies's product category is Biotechnology Reagents. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAG, Nanobodies & Alternative Antibody Scaffolds. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales